Diversified Trust Co Acquires 8,243 Shares of Ralliant Corporation $RAL

Diversified Trust Co increased its holdings in Ralliant Corporation (NYSE:RAL) by 93.9% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 17,026 shares of the company’s stock after acquiring an additional 8,243 shares during the quarter. Diversified Trust Co’s holdings in Ralliant were worth $708,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the business. Cetera Investment Advisers purchased a new stake in Ralliant during the second quarter valued at approximately $700,000. Russell Investments Group Ltd. purchased a new position in shares of Ralliant during the 2nd quarter worth $1,465,000. EverSource Wealth Advisors LLC bought a new stake in shares of Ralliant during the 2nd quarter valued at $39,000. First Trust Advisors LP bought a new stake in shares of Ralliant during the 2nd quarter valued at $2,013,000. Finally, Federated Hermes Inc. purchased a new stake in shares of Ralliant in the 2nd quarter worth $326,000.

Ralliant Trading Up 4.1%

Shares of RAL stock opened at $72.09 on Thursday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The stock has a fifty day simple moving average of $57.06 and a two-hundred day simple moving average of $50.94. The firm has a market capitalization of $8.07 billion and a PE ratio of -6.59. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $72.97.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.49 by $0.08. The business had revenue of $534.60 million for the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business’s revenue for the quarter was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, analysts predict that Ralliant Corporation will post 2.64 EPS for the current fiscal year.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on RAL. Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Wall Street Zen raised Ralliant from a “hold” rating to a “buy” rating in a research note on Saturday, June 20th. Oppenheimer lifted their price objective on Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. Finally, Morgan Stanley boosted their price objective on Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research note on Tuesday. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Ralliant presently has an average rating of “Moderate Buy” and a consensus target price of $69.00.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.